Cargando…

Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments

SIMPLE SUMMARY: Chemo- and radiotherapy have an outstanding function in cancer treatment. In the last few years, in order to reduce the occurrence of adverse effects and to increase the efficacy of these treatments, there has been a growing interest in bringing together chemotherapeutic agents and i...

Descripción completa

Detalles Bibliográficos
Autores principales: González, Alicia, Alonso-González, Carolina, González-González, Alicia, Menéndez-Menéndez, Javier, Cos, Samuel, Martínez-Campa, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268559/
https://www.ncbi.nlm.nih.gov/pubmed/34209857
http://dx.doi.org/10.3390/cancers13133263
_version_ 1783720383920209920
author González, Alicia
Alonso-González, Carolina
González-González, Alicia
Menéndez-Menéndez, Javier
Cos, Samuel
Martínez-Campa, Carlos
author_facet González, Alicia
Alonso-González, Carolina
González-González, Alicia
Menéndez-Menéndez, Javier
Cos, Samuel
Martínez-Campa, Carlos
author_sort González, Alicia
collection PubMed
description SIMPLE SUMMARY: Chemo- and radiotherapy have an outstanding function in cancer treatment. In the last few years, in order to reduce the occurrence of adverse effects and to increase the efficacy of these treatments, there has been a growing interest in bringing together chemotherapeutic agents and ionizing radiation with other adjuvant therapies, antiangiogenic therapy being an example. Within the antitumor actions of melatonin is the inhibition of angiogenesis in diverse cancer types. In this review, we summarize present knowledge on the act of melatonin as a promising cancer cells sensitizer molecule to chemo- and radiotherapy through antiangiogenic actions. ABSTRACT: Melatonin is a hormone with different functions, antitumor actions being one of the most studied. Among its antitumor mechanisms is its ability to inhibit angiogenesis. Melatonin shows antiangiogenic effects in several types of tumors. Combination of melatonin and chemotherapeutic agents have a synergistic effect inhibiting angiogenesis. One of the undesirable effects of chemotherapy is the induction of pro-angiogenic factors, whilst the addition of melatonin is able to overcome these undesirable effects. This protective effect of the pineal hormone against angiogenesis might be one of the mechanisms underlying its anticancer effect, explaining, at least in part, why melatonin administration increases the sensitivity of tumors to the inhibitory effects exerted by ordinary chemotherapeutic agents. Melatonin has the ability to turn cancer totally resistant to chemotherapeutic agents into a more sensitive chemotherapy state. Definitely, melatonin regulates the expression and/or activity of many factors involved in angiogenesis which levels are affected (either positively or negatively) by chemotherapeutic agents. In addition, the pineal hormone has been proposed as a radiosensitizer, increasing the oncostatic effects of radiation on tumor cells. This review serves as a synopsis of the interaction between melatonin and angiogenesis, and we will outline some antiangiogenic mechanisms through which melatonin sensitizes cancer cells to treatments, such as radiotherapy or chemotherapy.
format Online
Article
Text
id pubmed-8268559
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82685592021-07-10 Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments González, Alicia Alonso-González, Carolina González-González, Alicia Menéndez-Menéndez, Javier Cos, Samuel Martínez-Campa, Carlos Cancers (Basel) Review SIMPLE SUMMARY: Chemo- and radiotherapy have an outstanding function in cancer treatment. In the last few years, in order to reduce the occurrence of adverse effects and to increase the efficacy of these treatments, there has been a growing interest in bringing together chemotherapeutic agents and ionizing radiation with other adjuvant therapies, antiangiogenic therapy being an example. Within the antitumor actions of melatonin is the inhibition of angiogenesis in diverse cancer types. In this review, we summarize present knowledge on the act of melatonin as a promising cancer cells sensitizer molecule to chemo- and radiotherapy through antiangiogenic actions. ABSTRACT: Melatonin is a hormone with different functions, antitumor actions being one of the most studied. Among its antitumor mechanisms is its ability to inhibit angiogenesis. Melatonin shows antiangiogenic effects in several types of tumors. Combination of melatonin and chemotherapeutic agents have a synergistic effect inhibiting angiogenesis. One of the undesirable effects of chemotherapy is the induction of pro-angiogenic factors, whilst the addition of melatonin is able to overcome these undesirable effects. This protective effect of the pineal hormone against angiogenesis might be one of the mechanisms underlying its anticancer effect, explaining, at least in part, why melatonin administration increases the sensitivity of tumors to the inhibitory effects exerted by ordinary chemotherapeutic agents. Melatonin has the ability to turn cancer totally resistant to chemotherapeutic agents into a more sensitive chemotherapy state. Definitely, melatonin regulates the expression and/or activity of many factors involved in angiogenesis which levels are affected (either positively or negatively) by chemotherapeutic agents. In addition, the pineal hormone has been proposed as a radiosensitizer, increasing the oncostatic effects of radiation on tumor cells. This review serves as a synopsis of the interaction between melatonin and angiogenesis, and we will outline some antiangiogenic mechanisms through which melatonin sensitizes cancer cells to treatments, such as radiotherapy or chemotherapy. MDPI 2021-06-29 /pmc/articles/PMC8268559/ /pubmed/34209857 http://dx.doi.org/10.3390/cancers13133263 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
González, Alicia
Alonso-González, Carolina
González-González, Alicia
Menéndez-Menéndez, Javier
Cos, Samuel
Martínez-Campa, Carlos
Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
title Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
title_full Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
title_fullStr Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
title_full_unstemmed Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
title_short Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
title_sort melatonin as an adjuvant to antiangiogenic cancer treatments
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268559/
https://www.ncbi.nlm.nih.gov/pubmed/34209857
http://dx.doi.org/10.3390/cancers13133263
work_keys_str_mv AT gonzalezalicia melatoninasanadjuvanttoantiangiogeniccancertreatments
AT alonsogonzalezcarolina melatoninasanadjuvanttoantiangiogeniccancertreatments
AT gonzalezgonzalezalicia melatoninasanadjuvanttoantiangiogeniccancertreatments
AT menendezmenendezjavier melatoninasanadjuvanttoantiangiogeniccancertreatments
AT cossamuel melatoninasanadjuvanttoantiangiogeniccancertreatments
AT martinezcampacarlos melatoninasanadjuvanttoantiangiogeniccancertreatments